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Abstract: Background: Mesenchymal stromal cells (MSCs) have the capacity for self-renewal and
multi-differentiation, and for this reason they are considered a potential cellular source in regenera-
tive medicine of cartilage and bone. However, research on this field is impaired by the predisposition
of primary MSCs to senescence during culture expansion. Therefore, the aim of this study was to gen-
erate and characterize immortalized MSC (iMSC) lines from aged donors. Methods: Primary MSCs
were immortalized by transduction of simian virus 40 large T antigen (SV40LT) and human telom-
erase reverse transcriptase (hTERT). Proliferation, senescence, phenotype and multi-differentiation
potential of the resulting iMSC lines were analyzed. Results: MSCs proliferate faster than primary
MSCs, overcome senescence and are phenotypically similar to primary MSCs. Nevertheless, their
multi-differentiation potential is unbalanced towards the osteogenic lineage. There are no clear
differences between osteoarthritis (OA) and non-OA iMSCs in terms of proliferation, senescence,
phenotype or differentiation potential. Conclusions: Primary MSCs obtained from elderly patients
can be immortalized by transduction of SV40LT and hTERT. The high osteogenic potential of iM-
SCs converts them into an excellent cellular source to take part in in vitro models to study bone
tissue engineering.
Keywords: bone repair; immortalization; mesenchymal stromal cells; cell differentiation; osteogene-
sis; senescence
1. Introduction
Injuries and diseases in cartilage and bone are the main reasons of disability for aged
patients, and their prevalence is predicted to increase together with the average age of the
population [1–4]. Human bone marrow-derived mesenchymal stromal cells (MSCs) are self-
renewing, multipotent progenitors of osteoblasts, adipocytes and chondrocytes [5]. Thanks
to their multi-differentiation potential and proliferative capacities, MSCs are potential
cell candidates for cartilage and bone tissue engineering [6–9]. In addition, immortalized
MSC lines can be helpful to the development of in vitro models for bone diseases and
regeneration studies [10–14]. However, MSCs obtained from aged donors show reduced
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proliferation and differentiation potential and are prone to senesce in vitro, which limits
their usefulness for research [6–8,15].
Cell senescence is caused by telomere shortening or other types of cellular stress and
results in the acquisition of a senescent phenotype, characterized by enlarged cytoplasm,
increased lysosomal content and senescence-associated ß-galactosidase (SA-ß-Gal) activ-
ity. Telomere shortening and the resulting chromosomal instability cause the so-called
replicative senescence, while other types of cellular stress, including DNA damage or
oncogenic signals, cause stress-induced premature senescence (Carnero et al., 2015; Lunyak,
Amaro-Ortiz and Gaur, 2017; Schmeer et al., 2019).
During in vitro culture, the same processes that promote senescence in vivo take place:
due to the propagation of the cells, telomeres are shortened, DNA damage is accumu-
lated, and other types of cell stress are produced (Wagner et al., 2009; Medeiros Tavares
Marques et al., 2017). As a result of in vitro aging, MSCs display telomere shortening,
decline of their growth rate and colony forming capacity, and changes in their differ-
entiation potential from osteogenic to adipogenic (Honoki and Tsujiuchi, 2013), termed
“adipogenic switch” (Ok, Song and Hwang, 2018). The predisposition of aged MSCs to
senesce in vitro may be overcome by immortalization, which can be achieved by trans-
duction of certain genes. Since cartilage and bone disorders like osteoarthritis (OA) are
more frequent in the aged population, some efforts have been made to overcome MSCs
predisposition to senescence in vitro [16–19]. Different strategies have been applied to
give an unlimited growth capacity to MSCs, mainly involving the transduction of viral
genes and/or human telomerase reverse transcriptase (hTERT) [16–18,20–22]. Simian virus
40 large T antigen (SV40LT), as well as other viral genes, avoids cell cycle detention by
meddling with Rb- and p53-mediated pathways [23], whilst hTERT avoids telomere short-
ening and therefore the DNA damage-induced senescence [24,25]. It is unknown which
genetic alterations are required for MSC immortalization, but it is thought that it implies
the suppression of both replicative and stress-induced senescence. The transduction of
MSCs with only hTERT [20,22,26–28], E6/E7 [20] or SV40LT [16] eventually go through
senescence, while the mix of E6/E7 or SV40LT with hTERT provides efficient immortalized
MSCs [18,22] and adipose-derived stem cells [29].
We previously developed a method suitable for immortalizing MSCs derived from
aged donors by spinoculation of SV40LT and hTERT. In this way, we previously generated
four immortalized mesenchymal cell (iMSC) lines: three derived from three hip OA patients,
and one derived from a hip fracture patient without OA [30]. In this study, we generated
two iMSC lines by immortalization of primary MSCs derived from two elderly patients
with hip fractures and without OA. These iMSC lines were characterized and results
obtained from non-OA iMSC lines were compared with OA ones.
2. Results
2.1. SV40LT and hTERT Expression in Transduced MSCs
Expression of both transgenes, SV40LT and eGFP-hTERT, was detected in both lines
of transduced MSCs. Immunostaining studies allowed the detection of SV40LT by red
fluorescence and eGFP-hTERT by green fluorescence. Regarding SV40LT expression, it
showed a “nucleolar exclusion” arrangement, while eGFP-hTERT expression was found
in both nucleoplasm and nucleoli (Figure 1). Moreover, by means of qPCR, hTERT and
SV40LT expression was found in both immortalized cell lines, but not found in their
primary parental cells.




Figure 1. SV40LT and eGFP-hTERT immunostaining of iMSC#12 and iMSC#13; eGFP-hTERT is 
shown in green, SV40LT is shown in red and Hoechst staining is shown in blue. Scale bar: 50 µm. 
2.2. Senescence-Associated ß-Gal Activity of Transduced MSCs 
After more than 40 passages, both iMSC#12 and iMSC#13 showed almost no senes-
cence-associated ß-galactosidase (SA-ß-Gal) activity (Figure 2a,b), since 2.5 ± 0.6% of the 
cells were ß-Gal-positive in iMSC#12 and 1.8 ± 0.3% of the cells were ß-Gal-positive in 
iMSC#13. Oppositely, in primary MSC#12 at the fourth passage, 57.9% of cells were posi-
tive for SA-ß-Gal activity (Figure 2c). There were no significant differences among OA and 
non-OA iMSCs regarding SA-ß-Gal activity (p-value = 0.7000). 
 
Figure 2. SA-ß-Gal stained iMSC#12 (a), iMSC#13 (b) and primary MSCs at the fourthpassage (c). 
Images obtained by phase contrast microscope. SA-ß-Gal activity is shown in blue. Magnification: 
100×. 
2.3. Proliferative Capacity of Transduced MSCs 
For more than half a year, iMSC#12 and iMSC#13 were cultured upon 100 population 
doublings (PDs). For both immortalized cell lines, a continuous growth ratio was evi-
denced after regression analysis (R > 0.95 and p-value < 0.0001) (Figure 3). Mean genera-
tion time of immortalized cell lines within the 15th and the 50th passages was 2.2 ± 0.7 
days for iMSC#12 and 2.0 ± 0.7 days for iMSC#13. No significant differences were found 
among OA and non-OA iMSCs regarding generation time (p-value = 0.1345). 
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Figure 2. SA-ß-Gal stained iMSC#12 (a), iMSC#13 (b) and primary MSCs at the fourthpassage (c). Im-
ages obtained by phase contrast microscope. SA-ß-Gal activity is shown in blue. Magnification: 100×.
2.3. Proliferative Capacity of Transduced MSCs
For more than half a year, iMSC#12 and iMSC#13 were cultured upon 100 population
doublings (PDs). For both immortalized cell lines, a continuous growth ratio was evidenced
after regression analysis (R > 0.95 and p-value < 0.0001) (Figure 3). Mean generation time
of immortaliz d cell li es within the 15th and the 50th passages was 2.2 ± 0.7 days for
iMSC#12 and 2.0 ± 0.7 days for iMSC#13. No significant differences wer found among
OA and non-OA iMSCs regarding gene ation time (p-value = 0.1345).
2.4. Mesenchymal Surface Marker Express on in Transduced MSCs
A phenotypical study of both transduced cell lines was developed. For this purpose,
the expression levels of several mesenchymal (CD29, CD44, CD73, CD90 and CD105)
and hematopoietic (CD34 and CD45) surface markers was determined in primary MSCs,
SV40LT-transduced MSCs (T-MSCs) and iMSCs #12 and #13. In all cases, more than 93% of
the cells analyzed were positive for CD29, CD44 and CD90. For CD73, T-MSCs showed a
58.7% of expression, which was lower than its expression in primary and immortalized,
hTERT-transduced MSCs. CD105 expression increased from primary MSCs to iMSCs, but
it decreased in late- versus early passage immortalized cell lines. In all cases, cell positivity
for hematopoietic markers (CD34 and CD45) was 2.1% or less (Table 1).
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Figure 3. Number of population doublings (PDs) accumulated by both immortalized cell lines 
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a given subculture, and log is the natural logarithm). 
2.4. Mesenchymal Surface Marker Expression in Transduced MSCs 
A phenotypical study of both transduced cell lines was developed. For this purpose, 
the expression levels of several mesenchymal (CD29, CD44, CD73, CD90 and CD105) and 
hematopoietic (CD34 and CD45) surface markers was determined in primary MSCs, 
SV40LT-transduced MSCs (T-MSCs) and iMSCs #12 and #13. In all cases, more than 93% 
of the cells analyzed were positive for CD29, CD44 and CD90. For CD73, T-MSCs showed 
a 58.7% of expression, which was lower than its expression in primary and immortalized, 
hTERT-transduced MSCs. CD105 expression increased from primary MSCs to iMSCs, but 
it decreased in late- versus early passage immortalized cell lines. In all cases, cell positivity 
for hematopoietic markers (CD34 and CD45) was 2.1% or less (Table 1). 
Table 1. Phenotypical analysis to determine the mesenchymal and hematopoietic surface markers’ 
expression pattern in primary MSCs, T-MSCs and iMSCs at different (early and late) passages. Pas-
sage is represented as the number of subcultures as (1) primary MSCs, (2) T-MSCs and (3) iMSCs. 
Data from primary MSC#13 and T-MSC#13 could not be obtained because of limited cell number, 
and therefore only primary MSC#12 and T-MSC#12 are shown. 
Cells Passage CD29 CD44 CD73 CD90 CD105 CD34 CD45 
Primary MSCs 3 93.3% 95.2% 71.1% 98.5% 69.8% 0.2% 1.9% 
T-MSCs (3 + 4) 98.1% 98.9% 58.7% 98.4% 77.0% 2.1% 0.8% 
iMSC#12 (3 + 4 + 12) 97.4% 96.8% 85.6% 99.5% 80.1% 0.0% 0.0% 
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iMSC#13 (PD > 100) (3 + 3 + 44) 97.9% 98.2% 86.1% 98.3% 90.2% 0.5% 0.6% 
2.5. Multipotency of Transduced MSCs 
To find out if transduced cells showed multi-differentiation potential, primary MSCs, 
T-MSCs and iMSCs were grown on osteogenic, adipogenic and chondrogenic differentia-
tion medium. The ability for multilineage differentiation towards the specific lineages was 
assessed by molecular and histological studies. 
2.5.1. Histological Analysis 
Primary MSCs, T-MSCs and iMSCs retained osteogenic potential since they were ca-
pable of differentiating into osteocytes after three weeks of osteogenic induction. Their 
osteogenic potentials were compared by Alizarin Red staining, which stains calcium phos-
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(iMSC#12 and #13) versus days in culture. PDs were calculated as (log Nf − log Ni)/log 2 (where Nf
is the cell number at the end of a given subculture, Ni is the cell number used as inoculum to begin a
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Table 1. Phenotypical analysis to determine the mesenchymal and hematopoietic surface markers’ expression pattern
in primary MSCs, T-MSCs and iMSCs at different (earl and late) passages. Passage i repres nted as the number of
subcultures as (1) primary MSCs, (2) T-MSCs and (3) iMSCs. Data from primary MSC#13 and T-MS #13 could not be
obtained because of limited cell number, and therefore only primary MSC#12 and T-MSC#12 are shown.
Cells Passage CD29 CD44 CD73 CD90 CD105 CD34 CD45
Primary MSCs 3 93.3% 95.2% 71.1% 98.5% 69.8% 0.2% 1.9%
T-MSCs (3 + 4) 98.1% 98.9% 58.7% 98.4% 77.0% 2.1% 0.8%
iMSC#12 (3 + 4 + 12) 97.4% 96.8% 85.6% 99.5% 80.1% 0.0% 0.0%
iMSC#12 (PD > 100) (3 + 4 + 43) 97.8% 99.3% 82.1% 96.5% 78.1% 0.7% 0.2%
iMSC#13 (3 + 3 + 13) 99.3% 99.4% 98.8% 99.9% 97.7% 0.3% 0.9%
iMSC#13 (PD > 100) (3 + 3 + 44) 97.9% 98.2% 86.1% 98.3% 90.2% 0.5% 0.6%
2.5. Multipotency of Transd ced MSCs
To find out if transduced cells showed multi-differentiation potential, primary MSCs,
T-MSCs and iMSCs were grown on osteogenic, adipogenic and chondrogenic differentiation
medium. The ability for multilineage differentiation towards the specific lineages was
assessed by molecular and histological studies.
2.5.1. Histological Analysis
Primary MSCs, T-MSCs and iMSCs retained osteogenic potential since they were
capable of differentiating into osteocytes after three weeks of osteogenic induction. Their
osteogenic potentials were compared by Alizarin Red staining, which stains calcium
phosphate deposits in red. The mineralized area was similar between primary MSCs
(4th passage) (Figure 4a) and T-MSCs (8th passage) (Figure 4b) and moderately larger in
iMSCs (50th passage) (Fig re 4c,d). Primary MSCs grown on control medium did not
show mineralization (Figure 4e), but T-MSCs control evidenced a very slight degree of
mineralization (Figure 4f). Both li es of iMSCs grown on control medium were almost
negative for Alizarin Red staining (Figure 4g,h).
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Figure 4. Mineralization analysis by means of Alizarin Red staining of primary MSCs, T-MSCs and
iMSCs #12 and #13 after 3 weeks cultured in osteogenic medium (a–d) or grown in control medium
(20%FBS/DMEM) (e–h). For each sample, the average percentage of the area stained by Alizarin Red
is indicated. Information from primary parental MSC#13 and T-MSC#13 was not acquired because of
cell number restrictions, and therefore only primary MSC#12 and T-MSC#12 are shown. Scale bar:
100 µm.
Primary MSCs, T-MSCs and iMSCs adipogenic potentials were compared by Oil Red
O staining, which stains intracellular lipid droplets in red. Adipogenic differentiation
capacity of primary MSCs, T-MSCs and iMSCs was contrasted by Oil Red O dye, which
stains lipid vacuoles in red. Primary MSCs (Figure 5a) experienced weaker Oil Red O
staining than T-MSCs (Figure 5b), although primary MSCs were able to form more mature
adipocytes, whereas T-MSCs and iMSCs showed smaller lipid vacuoles (Figure 5b–d).
Primary MSCs grown on control medium were hardly dyed with Oil Red O (Figure 5e),
while T-MSCs and iMSC#12 showed some positivity (Figure 5f,g). When cultured in control
medium, iMSC#13 was negative for this staining (Figure 5h).
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Figure 5. Adipogenic potential analysis of pri ary MSCs, T-MSCs and iMSCs #12 and #13 after
3 weeks cultured in adipogenic ediu (a–d) or gro n in control medium (20%FBS/D E ) (e–h).
For each sample, the average percentage of the area stained with Oil Red O is indicated. Information
from primary MSC#13 and T-MSC#13 was not acquired because of cell number restrictions, and
therefore only primary MSC#12 and T-MSC#12 are shown. Scale bar: 50 µm.
As for chondrogenic induction, iMSC#12 did not form aggregates when submitted
to the hanging drop method, and aggregates formed by iMSC#13 could not be analyzed
because they were not big enough to allow for the performance of histological techniques.
When submitted to pellet culture, neither iMSC#12 nor iMSC#13 was able to produce the
extracellular matrix necessary to keep the integrity of the aggregates.
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2.5.2. Molecular Analysis
The expression of proliferating cell nuclear antigen (PCNA), which is present only in
actively proliferating cells, and OCT4B1, which is related with multipotency, was analyzed
in undifferentiated OA (#6, #8 and #10) and non-OA (#9, #12 and #13) iMSCs and their pri-
mary parental MSCs. The level of expression of PCNA increased in iMSCs compared with
primary MSCs (p-value = 0.0022), but no significant differences were found between OA
and non-OA iMSCs (p-value = 1.0000) (Figure 6a). OCT4B1 expression was also increased
in iMSCs compared with primary MSCs (p-value = 0.0286), but, again, no significant
differences were found between OA and non-OA iMSCs (p-value = 0.2000) (Figure 6b).
Furthermore, the expression of osteogenic and adipogenic-related genes was compared
in primary, T-MSCs and iMSCs in cell line #12. The highest expression of osteocalcin
(OCN) was detected in iMSCs. Runt-related transcription factor 2 (Runx2) expression was
higher in MSCs than in T-MSCs and iMSCs, but the highest expression of the transcription
factor Sp7 expression was detected in iMSCs (Figure 6c). The highest expression of both
adipogenesis-related genes was found in iMSCs. Fatty acid binding protein 4 (FABP4) was
similarly expressed in MSCs and T-MSCs, while adiponectin (APN) was more expressed in
primary MSCs (Figure 6d).
The expression of chondrogenesis-related genes was analyzed in spheroids formed by
iMSCs (cell lines #6, #9 and #10) and primary articular chondrocytes (Figure 7). Upon chon-
drogenic induction, the expression of the chondrogenesis-related SRY-box transcription
factor 9 (Sox9) was down-regulated in iMSCs, while the expression of the osteogenesis-
related transcription factor Runx2 and type X collagen (Col10A1), a marker of chondrocyte
hypertrophy, was up-regulated. In addition, the expression of Runx2 and Col10A1 was
higher in iMSC spheroids than in particular chondrocyte spheroids, while the expression
of Sox9 was lower. Type II collagen (Col2A1) and aggrecan expression was detected in
chondrocyte spheroids but not detected in iMSC spheroids by qPCR.
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lt S s derived from aged donors are prone to senesce duri g in vitro
culture, transduction of immortalization genes which repress both telomere shortening
and p53- and Rb-mediated pathways allows them to acquire an unlimited proliferation
potential [7,22,31]. The limitations associated with primary MSCs have led to the genera-
tion of several immortalized MSCs lines [16–18,21] which have many in vitro applications,
such as the development of models of disease [13,14] and the assay of scaffolds for cartilage
and bone regeneration [10–12].
In this study, primary MSCs derived from aged donors were immortalized by sequen-
tial spinoculation of SV40LT and hTERT, as previously described [30]. Immortalized MSCs
overcame senescence and acquired an unlimited proliferation potential while maintaining
most of the characteristics of MSCs. Both iMSC lines generated in this study showed high
proliferation rates, unlike late-passage primary MSCs derived from aged donors. This fast
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proliferation may be due to the combination of SV40LT and hTERT transduction, which
exerts a synergistic effect over MSC growth rate [29,32].
In addition, both iMSC lines showed high expression of the mesenchymal surface
markers CD29, CD44, CD73, CD90 and CD105. However, the expression of CD73 was
lower in T-MSCs. The expression of CD73 can be reduced after several passages, as has
been described by other authors [33], and the loss of its expression can be accompanied by a
decrease in cell growth rate. Accordingly, the reduced expression of CD73 in T-MSCs could
be related to the aging of these cells, which are lacking a mechanism to repress telomere
shortening and, therefore, are not completely immortalized.
Moreover, the expression of CD105 was higher in iMSCs and T-MSCs than in primary
MSCs. We have previously observed that CD105 can either reduce or increase its expression
from primary to immortalized cells [30], and its expression can also be reduced with
passaging [29,33–36]. The role that CD105 expression plays in MSCs is still unclear [37].
There are two isoforms of CD105: L-endoglin, which is related to tumour development
and angiogenesis, and S-endoglin, which has been described to supress tumour invasion
and to have an anti-angiogenic effect [38,39]. The expression of S-endoglin could thus be
related to the resistance of MSCs to undergo malignant transformation [40], and the loss
of CD105 could be related to the acquisition of oncogenic potential. Taking together the
results shown here and those from our previous study [30], only two out of six iMSC lines,
iMSC#8 and iMSC#9, showed low levels of CD105, and these two cell lines were the only
ones able to grow independently of anchorage in a soft agar assay.
The expression levels of genes associated with stemness are known to be altered after
the transduction with immortalization genes [41]. One of these genes is OCT4, whose
splice variant OCT4B1 is related to the maintenance of an undifferentiated state in both
pluripotent stem cells and human somatic cells [42–44]. In primary MSCs, OCT4 has been
related to higher proliferation and potency, and its level of expression gradually decreases
as the number of passages increases [45]. In this study, iMSCs expressed higher levels of
OCT4B1 than their primary parental cells, which could indicate a higher level of stemness.
One essential characteristic of MSCs is their multi-differentiation potential into os-
teoblasts, chondroblastas and adipocytes [5,46,47], which may be altered by immortal-
ization [30]. Osteogenesis is the default differentiation pathway for MSCs [5,21,48], and
immortalized MSCs are able to form bone both in vitro [49–51] and in vivo [21,52,53].
The osteogenic potential of immortalized MSCs is usually equal or higher than that of
primary MSCs [16,54], while their chondrogenic potential is generally poor [17,21,26,55].
Immortalized MSCs and osteoprogenitor cells have often been reported to be able to
differentiate into adipocytes [49,56–59], but adipogenic potential may be reduced after
immortalization [26,60,61].
In this study, iMSCs showed higher osteogenic potential than their primary parental
T-MSCs and MSCs, with stronger Alizarin Red staining and higher OCN expression. In
the study by Tsai et al. (2010), the hTERT- and E6/E7-transduced immortalized MSC line
3a6 was also more osteogenic than the their parental KP cells, which were transduced
with E6/E7 only. On the other hand, hTERT-transduced but not immortalized MSCs
have been found to have a reduced osteogenic potential in comparison with their primary
parental cells [62]. In cell line #12, iMSCs expressed the highest levels of Sp7 and OCN
but lower levels of Runx2 than primary MSCs. Runx2 is a transcription factor required
for the commitment of MSCs to pre-osteoblasts, while subsequent OCN production and
differentiation into mature osteoblasts is regulated by a concerted action of Runx2 and Sp7.
Sp7 is, at the same time, a downstream target of Runx2 [63]. Poor mineralization combined
with high levels of Runx2 and low levels of OCN may indicate an immature state of the
osteoblasts derived from primary MSCs and T-MSCs, which suggests that immortalization
could be beneficial for the bone-forming ability of MSCs.
Both iMSC lines generated in this study were able to differentiate into the adipogenic
lineage to some degree, but they did not give rise to mature adipocytes, as we had already
observed [30]. Unlike iMSCs and T-MSCs, primary MSCs did form more mature adipocytes,
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as evidenced by Oil Red O staining. MSCs have been described to become more adipogenic
during in vitro aging [64], but the adipogenic potential of immortalized MSCs has been
described to be progressively reduced throughout in vitro expansions [22,60]. However,
iMSC#12 expressed higher levels of the adipogenic markers APN and FABP4 than their
primary parental cells upon adipogenic induction. APN and FABP4 are responsible for the
formation of mature adipocytes [65], and their up-regulation upon adipogenic induction
demonstrates the potential of iMSCs to differentiate into this cell lineage, although longer
exposure to adipogenic stimuli may be needed to generate mature adipocytes.
Unfortunately, the chondrogenic potential of the non-OA iMSC lines generated in this
study could not be evaluated due to their inability to form three-dimensional aggregates or
the small size of the aggregates after 21 days of chondrogenic induction. Nonetheless, other
authors have described that immortalized MSCs have the same predisposition to hyper-
trophy than primary MSCs [48], with type X collagen expression [21,55] and low-quality
cartilage production [66]. Gene expression analysis in previously generated iMSCs shows
that these cells up-regulate the osteogenic transcription factor Runx2 and the hypertrophic
marker type X collagen upon chondrogenic induction. It has been proposed that the low
chondrogenic potential of MSCs is due to their committal to the endochondral ossification
pathway [48].
This shift in the differentiation potential of MSCs after immortalization can be a result
of either transduction or passaging. In addition, the differences found among the multi-
differentiation abilities of MSCs, T-MSCs and iMSCs could be derived from the selection
of cells during these processes. Extensive passaging leads to the selection of the cells
with the highest growth rates in polyclonal cultures [67]. Since MSCs are heterogeneous
cell populations, this arbitrary selection of cells will alter their properties, including their
multi-differentiation potential.
Both iMSC lines generated in this study were non-tumorigenic. In general, MSCs
have been described to be resistant to malignant transformation [34,68] and are able to
obtain an unlimited proliferation potential without aberrant growth control or oncogenic
features [28,34,52,54]. Other authors have also investigated the oncogenic potential of
immortalized MSCs in animal models, demonstrating that only immortalized MSCs trans-
duced with an additional proto-oncogene [34] or sub-cultured at low densities for more
than 200 PDs [36] are capable of forming tumours in immunodeficient mice.
In summary, this study has shown that primary MSCs derived from aged donors
can be immortalized by sequential spinoculation of SV40LT and hTERT, and that non-OA
iMSCs are not different from OA iMSCs in terms of proliferation, senescence, surface
makers expression and multi-differentiation potential. The high osteogenic potential of
these cells makes them ideal candidates to form part of in vitro tissue engineering models
for bone disease and regeneration studies.
4. Materials and Methods
4.1. Primary MSCs Isolation and Culture
The regional ethics committee of research from A Coruña-Ferrol (Spain, 2016/588)
approved this study. Bone marrow-derived MSCs were isolated from two male donors
(aged 88 and 95 years) with hip fractures who underwent orthopedic surgery and gave
written informed consent. Bone marrow cells were obtained as previously described [30,69]
and grown in Dulbecco’s modified Eagle’s medium (DMEM; Lonza, Madrid, Spain) with
20% foetal bovine serum (FBS, Gibco, Thermo Fisher Scientific, Madrid, Spain) and 1%
penicillin/streptomycin (P/S, Gibco) (20%FBS/DMEM). At 80–90% confluence cells were
sub-cultured with 0.1% trypsin-EDTA (Gibco). A 15-min pre-plating technique [70] was
employed in the first and second passages.
4.2. Primary MSCs Immortalization
Immortalization of primary MSCs was performed as described elsewhere [30]. Pri-
mary MSCs (third passage) were transduced by spinoculation using retrovirus produced
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by Phoenix Amphotropic cells (ATCC CRL-3213, ϕNX-A) [71]. Primary MSCs were trans-
duced with SV40LT, and SV40LT-transduced cells were subsequently transduced with
hTERT. ϕNX-A cells were transfected by employing two plasmids obtained from Addgene:
pBABE-hygro-eGFP-hTERT (Addgene plasmid #28169), deposited by Kathleen Collins [72],
and pBABE-puro-SV40LT (Addgene plasmid #13970), deposited by Thomas Roberts [73].
Plasmid DNA was diluted in with Opti-MEM (Gibco), and X-tremeGENE HP DNA Trans-
fection Reagent (Roche, Sigma-Aldrich Química S.A., Madrid, Spain) was added (3 µL per
µg of plasmid DNA).
After 24 h-incubation at 37 ◦C, the culture medium was changed, and the transfected
ϕNX-A cells were incubated during 48 h at 32 ◦C for retrovirus production. Retroviral
supernatants were then filtered using a 0.45 µm filter (Millipore, Burlington, MA, USA),
and hexadimethrine bromide (Sigma-Aldrich Química S.A.) was added to the retroviral
supernatant (8 µg/mL). MSCs were subjected to spinoculation at 800× g and 32 ◦C for
45 min, and thereafter incubated at 37 ◦C for 4 h. Then, fresh culture medium with
2 mM valproic acid (Cayman Chemical Company, Ann Arbor, MI, USA) was added to
the cells to induce transgene expression. After 72 h, fresh culture medium containing
2.5 µg/mL puromycin (Thermo Fisher Scientific) or 75 µg/mL hygromycin (AMRESCO,
VWR International) was added for selection of transduced MSCs. Transduced MSCs were
subsequently grown and sub-cultured just as primary MSCs.
4.3. Immunofluorescence of SV40LT and hTERT
In order to test the expression of SV40LT and hTERT, transduced MSCs were seeded in
8-well chamber slides (Millipore), fixed with 4% paraformaldehyde and permeabilized with
0.5% Triton X-100 (both from Sigma-Aldrich Química S.A.). Two primary antibodies were
incubated at 4 ◦C overnight: rabbit anti-GFP labelled with Alexa Fluor 488 dye (A-21311;
1:500; Invitrogen, Thermo Fisher Scientific) and mouse anti-SV40LT (SV40LT clone Pab 108;
1:100; Santa Cruz Biotechnology, Dallas, TX, USA).
After that, cells were washed with phosphate-buffered saline (PBS; Dako, Agilent
Technologies Spain S.L., Barcelona, Spain) and incubated at room temperature for one hour
with a secondary goat anti-mouse antibody labelled with Alexa Fluor 594 dye (A-11032;
1:1000; Invitrogen). Thereafter, cells were stained with Hoechst (bisBenzimide H 33342
trihydrochloride, Sigma-Aldrich Química S.A.) and slides were mounted with Glycergel
(Dako). The Olympus BX61 fluorescence microscope (Olympus Iberia S.A., Barcelona,
Spain) and a coupled Olympus DP70 digital camera (Olympus Iberia S.A.) were used to
obtain thefluorescence micrographs, using the cellSens Dimension software (Olympus
Iberia S.A.).
4.4. Senescence Activity
Senescence was tested in both cell lines of MSCs using the Senescence Cells Histo-
chemical Staining kit (Sigma-Aldrich Química S.A.) for cytochemical staining of SA-ß-Gal
activity. All staining was performed after 100 PDs and at three different passages. Images
of the cells were obtained with a Nikon Eclipse TS100 inverted microscope and a XM Full
HD digital camera after 16 h of incubation. Randomly, ten microscope fields were counted
for SA-ß-Gal-positive and negative cells to calculate the percentage of senescent cells, and
the results are shown as mean percentage ± standard error. As a control, primary fourth
passage MSCs were used.
4.5. Proliferation Analysis
The formula in Equation (1) [74] was used to calculate the proliferation of the trans-
duced cells as cumulative PDs. At each passage, cells were detached and counted to obtain
the initial and final cell numbers. The number of PDs per day was calculated at each
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passage to obtain the generation time for each cell line. Regression was used to analyze
proliferation rates of both cell lines.
PD =
log N f − log Ni
log 2
(1)
Equation (1). Formula employed to calculate population doubling (PD) at each pas-
sage, where Nf is the final cell number, Ni is the initial cell number, and log is the natu-
ral logarithm.
4.6. Flow Cytometric Analysis
Flow cytometry was used to analyze the expression of CD29, CD44, CD73, CD90 and
CD105, which are surface markers characteristic of MSCs, as well as the expression of CD34
and CD45, which are hematopoietic stem cells markers. After being split with 0.1% trypsin-
EDTA, cells were washed twice in Fluorescence Activated Cell Sorting (FACS) buffer (BD
Biosciences, Madrid, Spain). Incubation with fluorescent-labelled antibodies and isotype
controls (Table 2) was performed at 4 ◦C for 45 min. After washing, cells were resuspended
in FACS buffer and transferred to polypropylene tubes (NUNC, VWR International) for
data acquisition with the BD FACSCalibur flow cytometer (BD Biosciences). Obtained data
was analyzed using BD Cell-Quest Pro software (BD Biosciences). 105 cell events were
acquired as a minimum for each assay. Results were shown as percentage of positive cells.
Table 2. Isotype controls and antibodies conjugated with fluorescein isothiocyanate (FITC), phycoerythrin (PE) or PE/Cy5
used for flow cytometry.
Antibody Specificity Clone Source Dilution
FITC Mouse IgG1 Isotype Control - ICIG1 Immunostep 1:50
PE Mouse IgG1 Isotype Control - B11/6 Immunostep 1:50
PECy5 Mouse IgG1 Isotype Control - 1F8 Abcam 2:25
PE Mouse Anti-Human CD29 Human integrin β1 (ITGB1) VJ1/14 Immunostep 3:50
PE Mouse Anti-Human CD34 Hematopoietic progenitor cellantigen 1 (HPCA1) 581 BD Pharmingen 2:25
FITC Mouse Anti-Human CD44 Homing cellular adhesionmolecule (HCAM) IM7 BD Pharmingen 1:50
FITC Mouse Anti-Human CD45 Leukocyte common antigen (LCA) D3/9 Immunostep 3:50
PE Mouse Anti-Human CD73 Ecto-5′-nucleotidase (NT5E) AD2 Immunostep 3:50
PECy5 Mouse Anti-Human CD90 Thymocyte differentiationantigen 1 (Thy-1) 5E10 Immunostep 1:50
FITC Mouse Anti-Human CD105 Human Endoglin (ENG) SN6 AbD Serotec 1:50
4.7. Cell Differentiatin Induction
Multi-differentiation potential of primary and transduced MSCs was evaluated through
osteogenic, adipogenic and chondrogenic cell differentiation assays. For osteogenic and
adipogenic cell differentiation experiments, 2 × 104 cells were seeded on 8-well chamber
slides to perform histological analysis, while 105 cells were seeded on 6-well plates for
molecular analysis. Experiments were maintained for 21 days in hMSC Ostegenic Dif-
ferentiation Medium (Lonza) or StemPro Adipogenesis Differentiation Kit (Gibco) and
20%FBS/DMEM as a control.
For chondrogenic cell differentiation experiments, three-dimensional cell culture was
chosen [75]. Both hanging drop method and pellet cultures were employed to create cell
aggregates, which were subsequently incubated in hMSC Chondrogenic Differentiation
Medium supplemented with 10 ng/mL of human transforming growth factor β-3 (TGF-
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β3) (ProSpec-Tany TechnoGene, Rejovot, Israel) for 21 days. Cell aggregates were also
incubated for the same time in 20%FBS/DMEM as a control. Articular chondrocytes
obtained from one donor with hip OA who underwent orthopedic surgery (female, 81 years)
as described elsewhere [76] were submitted to the same differentiation protocol, and
chondrocyte spheroids were employed as a positive control of chondrogenesis.
4.8. Histological Analysis
After osteogenic and adipogenic induction, cells on chamber slides were fixed with
4% paraformaldehyde. For osteogenic differentiation, cells were stained with Alizarin Red,
and slides were mounted with DPX mounting medium (Surgipath, Leica Microsistemas
S.L., Barcelona, Spain). For adipogenic differentiation, cells were stained with Oil Red O,
and slides were mounted with Glycergel aqueous mounting medium. Chondrogenically-
differentiated cell aggregates were fixed with 3.7% formaldehyde (Panreac Química S.L.U.,
Barcelona, Spain), embedded in paraffin (Merck Millipore, Merck KGaA, Darmstadt, Ger-
many) and cut in a microtome.
Micrographs of slides were taken with the Olympus DP70 digital camera coupled
to the Olympus BX61 microscope and using the cellSens Dimension software. Stained
areas and staining intensity were evaluated quantitatively employing the ImageJ software
(National Institutes of Health, Bethesda, MD, USA). To measure staining intensity, optical
density (OD) was calculated using the formula OD = log (max intensity/mean intensity),
where log is the natural logarithm. An average of optical density and percentage of staining
was obtained from four different areas of each sample.
4.9. Molecular Analysis
RNA was isolated with TRIzol Reagent (Thermo Fisher Scientific) and chloroform
(Sigma-Aldrich Química S.A.), followed by an RNA precipitation step with isopropanol
(Sigma-Aldrich Química S.A.) and a washing step with ethanol (Sigma-Aldrich Química S.A.).
A reverse transcription-polymerase chain reaction (RT-PCR) was performed using the Su-
perScript VILO cDNA Synthesis kit, following the instructions of the kit (Thermo Fisher
Scientific), in an Applied Biosystems Veriti 96-Well Thermal Cycler (Thermo Fisher Scientific).
The RT-PCR employed program was 10 min at 25 ◦C, 120 min at 42 ◦C and 5 min at 85 ◦C.
Retrotranscription was performed with 2 µg of RNA when available, and obtained cDNA
was diluted 1:100; otherwise, the total amount of isolated RNA was retrotranscribed and
cDNA was diluted accordingly. Quantitative real-time polymerase chain reaction (qPCR)
was performed in a LightCycler 480 Instrument (Roche), using LightCycler 480 SYBR Green I
Master (Roche) and adding the specific primers for the genes shown in Table 3. The program
of qPCR consisted of 10 min of incubation at 95 ◦C, 35–45 amplification cycles (10 s at 95 ◦C,
5 s at 60 ◦C and 10 s at 70 ◦C), one melting cycle (5 s at 95 ◦C, 1 min at 65 ◦C and up to 97 ◦C
at 0.03 ◦C/s) and 20 s of cooling at 40 ◦C.
qPCR analysis was performed using the LightCycler 480 Relative Quantification soft-
ware (Roche). Relative gene expression levels (RELs) were calculated using the qbase+
software (Biogazelle, Zwijnaarde, Belgium). RELs of osteogenesis, adipogenesis, prolifera-
tion and multipotency related genes were scaled to the sample with the highest expression
of each gene. RELs of chondrogenesis-related genes in iMSC spheroids were scaled to
chondrocyte spheroids. Results are expressed as mean ± standard error. YWHAZ was the
most stable of the candidate reference genes tested, as determined by geNorm [77], and
therefore it was employed as the reference gene in qPCR assays.
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Table 3. Studied genes and respective primers employed for quantitative real-time PCR (qPCR) analysis.





Homo sapiens runt related transcription
factor 2 (RUNX2) TTACTTACACCCCGCCAGTC TATGGAGTGCTGCTGGTCTG
Homo sapiens Sp7 transcription
factor (SP7) TCCCCTGTTGCCATGGTTAT CCACCCATTCTTCAGGAGGT
Homo sapiens bone
gamma-carboxyglutamate protein (OCN) GGCGCTACCTGTATCAATGG TCAGCCAACTCGTCACAGTC
Homo sapiens adiponectin, C1Q and
collagen domain containing (APN) GGTGAGAAAGGAGATCCAGGT TGCTGAGCGGTATACATAGGC
Homo sapiens fatty acid binding
protein 4 (FABP4) GGATGATAAACTGGTGGTGGA CACAGAATGTTGTAGAGTTCAATGC
Simian virus 40 complete genome (SV40) TGGGGAGAAGAACATGGAAG AAATGAGCCTTGGGACTGTG
Homo sapiens telomerase reverse
transcriptase (hTERT) GCTAGTGGACCCCGAAGG CCTCCCTGACGCTATGGTT
Homo sapiens proliferating cell nuclear
antigen (PCNA) TAGACTTTCCTCCTTCCCGC TGCCTCCAACACCTTCTTGA
Homo sapiens POU class 5
homeobox 1 (POU5F1), transcript
variant 4 (OCT4B1)
AGGGAGAGGGAGAAGATGCT GAAGCAAAGTGAGGGAGCAC
Homo sapiens SRY-box transcription
factor 9 (SOX9) GTACCCGCACTTGCACAAC TCGCTCTCGTTCAGAAGTCTC
Homo sapiens collagen type X
alpha 1 chain (COL10A1) CACCTTCTGCACTGCTCATC GGCAGCATATTCTCAGATGGA
Homo sapiens collagen type II
alpha 1 chain (COL2A1) TGGTGCTAATGGCGAGAAG CCCAGTCTCTCCACGTTCAC
Homo sapiens aggrecan (ACAN) CGGTCTACCTCTACCCTAACCA GAGAAGGAACCGCTGAAATG
4.10. Colony Formation Assay
In order to assess the colony formation ability of transduced MSCs, 5 × 102 of these
cells were seeded in 6-well culture dishes and grown for one week. After this time,
transduced MSCs were washed with PBS, fixed with 4% paraformaldehyde and stained
with 0.1% crystal violet (Sigma-Aldrich Química S.A.). Stained colonies were visualized
with the Nikon SMZ 745T stereomicroscope, and pictures of the colonies were taken with a
coupled Nikon DS-Fi2 digital camera (Nikon Instruments Europe B.V.).
4.11. Soft Agar Assay
Oncogenic potential of transduced MSCs was studied with the soft agar colony for-
mation assay [78]. For each cell line, 3.75 × 103 cells/well were inoculated in 0.375% agar
(Sigma-Aldrich Química S.A.), layered on top of a 0.5% agar layer in 12-well culture dishes
(Costar Corning Incorporated) and incubated for 14 days. The resultant colonies were
visualized and photographed using a Nikon SMZ 745T stereomicroscope coupled to a
Nikon DS-Fi2 digital camera.
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